Price T Rowe Associates Inc Ascendis Pharma A/S Transaction History
Price T Rowe Associates Inc
- $935 Billion
- Q3 2025
A detailed history of Price T Rowe Associates Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,726,228 shares of ASND stock, worth $353 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,726,228
Previous 1,875,491
7.96%
Holding current value
$353 Million
Previous $324 Million
6.02%
% of portfolio
0.04%
Previous 0.04%
Shares
20 transactions
Others Institutions Holding ASND
# of Institutions
318Shares Held
65MCall Options Held
476KPut Options Held
142K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.1 Billion35.1% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.26MShares$1.08 Billion4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.11MShares$1.04 Billion13.88% of portfolio
-
Janus Henderson Group PLC London, X04.32MShares$884 Million0.41% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X04.27MShares$873 Million0.89% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...